1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Synthekine: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers STK-012, pembrolizumab KEYTRUDA®, pemetrexed - Advanced Solid Tumor, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Synthekine | 364 | 2022-01-25 | 2026-10-29 |
Carcinoma, Non-Small-Cell Lung (1)
Carboplatin (1) · Pemetrexed (1) · pembrolizumab (1)
Georgia (1) · Ireland (1) · Italy (1) · Poland (1) · Spain (1) · United States (1)
2025 (1)